Northern Trust Corp Cara Therapeutics, Inc. Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 85,310 shares of CARA stock, worth $25,593. This represents 0.0% of its overall portfolio holdings.

Number of Shares
85,310
Previous 369,706 76.92%
Holding current value
$25,593
Previous $96,000 72.92%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$0.26 - $0.38 $73,942 - $108,070
-284,396 Reduced 76.92%
85,310 $26,000
Q2 2024

Aug 14, 2024
SELL
$0.24 - $0.92 $5,064 - $19,412
-21,101 Reduced 5.4%
369,706 $96,000
Q1 2024

May 14, 2024
SELL
$0.52 - $1.05 $522 - $1,055
-1,005 Reduced 0.26%
390,807 $355,000
Q4 2023

Feb 13, 2024
SELL
$0.6 - $1.65 $15,235 - $41,896
-25,392 Reduced 6.09%
391,812 $289,000
Q3 2023

Nov 13, 2023
BUY
$1.67 - $3.33 $12,817 - $25,557
7,675 Added 1.87%
417,204 $700,000
Q2 2023

Aug 11, 2023
SELL
$2.83 - $4.94 $846,985 - $1.48 Million
-299,288 Reduced 42.22%
409,529 $1.16 Million
Q1 2023

May 15, 2023
SELL
$4.89 - $12.27 $105,325 - $264,283
-21,539 Reduced 2.95%
708,817 $3.48 Million
Q4 2022

Feb 13, 2023
BUY
$8.88 - $12.77 $45,376 - $65,254
5,110 Added 0.7%
730,356 $7.84 Million
Q3 2022

Nov 14, 2022
BUY
$8.24 - $12.56 $480,944 - $733,089
58,367 Added 8.75%
725,246 $6.79 Million
Q2 2022

Aug 12, 2022
BUY
$7.45 - $13.84 $861,637 - $1.6 Million
115,656 Added 20.98%
666,879 $6.09 Million
Q1 2022

May 13, 2022
SELL
$9.94 - $12.65 $178,661 - $227,371
-17,974 Reduced 3.16%
551,223 $6.7 Million
Q4 2021

Feb 08, 2022
SELL
$11.99 - $18.14 $269,834 - $408,240
-22,505 Reduced 3.8%
569,197 $6.93 Million
Q3 2021

Nov 15, 2021
SELL
$11.55 - $16.06 $34,014 - $47,296
-2,945 Reduced 0.5%
591,702 $9.14 Million
Q2 2021

Aug 13, 2021
BUY
$12.38 - $29.19 $1.28 Million - $3.03 Million
103,755 Added 21.14%
594,647 $8.49 Million
Q1 2021

May 12, 2021
SELL
$15.07 - $21.71 $537,260 - $773,983
-35,651 Reduced 6.77%
490,892 $10.7 Million
Q4 2020

Feb 11, 2021
SELL
$12.72 - $16.16 $81,382 - $103,391
-6,398 Reduced 1.2%
526,543 $7.97 Million
Q3 2020

Nov 16, 2020
SELL
$12.34 - $17.92 $440,932 - $640,317
-35,732 Reduced 6.28%
532,941 $6.78 Million
Q2 2020

Aug 14, 2020
BUY
$12.39 - $17.33 $475,305 - $664,813
38,362 Added 7.23%
568,673 $9.72 Million
Q1 2020

May 14, 2020
BUY
$9.12 - $17.78 $81,797 - $159,468
8,969 Added 1.72%
530,311 $7 Million
Q4 2019

Feb 14, 2020
SELL
$16.11 - $25.98 $145,553 - $234,729
-9,035 Reduced 1.7%
521,342 $8.4 Million
Q3 2019

Nov 13, 2019
BUY
$18.28 - $26.91 $1.88 Million - $2.76 Million
102,721 Added 24.02%
530,377 $9.7 Million
Q2 2019

Aug 13, 2019
BUY
$17.68 - $21.57 $29,136 - $35,547
1,648 Added 0.39%
427,656 $9.19 Million
Q1 2019

May 13, 2019
BUY
$14.41 - $19.64 $26,485 - $36,098
1,838 Added 0.43%
426,008 $8.36 Million
Q4 2018

Feb 12, 2019
BUY
$12.45 - $23.47 $10,109 - $19,057
812 Added 0.19%
424,170 $5.52 Million
Q3 2018

Nov 14, 2018
BUY
$17.57 - $23.95 $1.52 Million - $2.08 Million
86,777 Added 25.78%
423,358 $10.1 Million
Q2 2018

Sep 18, 2018
SELL
$11.6 - $19.27 $24,325 - $40,409
-2,097 Reduced 0.62%
336,581 $6.45 Million
Q2 2018

Aug 14, 2018
BUY
$11.6 - $19.27 $218,544 - $363,046
18,840 Added 5.89%
338,678 $6.49 Million
Q1 2018

May 09, 2018
BUY
$11.77 - $16.08 $40,065 - $54,736
3,404 Added 1.08%
319,838 $3.96 Million
Q4 2017

Feb 14, 2018
SELL
$11.86 - $14.08 $134,397 - $159,554
-11,332 Reduced 3.46%
316,434 $3.87 Million
Q3 2017

Nov 13, 2017
BUY
$12.6 - $16.34 $4.13 Million - $5.36 Million
327,766
327,766 $4.49 Million

Others Institutions Holding CARA

# of Institutions
74
Shares Held
12.8M
Call Options Held
0
Put Options Held
0
View Full List

About Cara Therapeutics, Inc.

CARA Quotes by TradingView
  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $16.1M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email